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Abstract
Background: We studied the beta-lactamases of an E. aerogenes isolate recovered from the blood of a two-year-
old patient. The isolate demonstrated a disk-diffusion phenotype typical for an AmpC-ESBL co-producer.
Methods: Microbiology studies were performed according to standard protocols. The resistance gene was
identified by transconjugation and cloning experiments.
Results: By transconjugation only a narrow spectrum beta-lactamase (TEM-1) encoded on a small plasmid was
transmitted. The ESBL was cloned and expressed in an E. coli host. Sequence analysis of the recombinant plasmid
revealed blaSHV-12 associated to the insertion sequence, IS26.
Conclusion: This is the first study demonstrated the occurrence of SHV-12 in Nigeria.
Background
Enterobacter species, in particular, E. cloacae and E.
aerogenes are able to compromise antibacterial treat-
ment by over expressing the chromosomal AmpC beta-
lactamase [1,2]. Emergence and spread of Class A
extended-spectrum beta-lactamases (ESBLs) among
these species are further complications [3].
ESBLs confer resistance to expanded-spectrum beta-
lactam antibiotics. The majority of these enzymes are
derived by amino acid substitutions from the narrow
s p e c t r u mp r e c u r s o r s ,T E M - 1 ,2a n dS H V - 1 .T E M - t y p e
ESBLs generally disseminate on transposons, Tn1, Tn2
and Tn3 [4]. SHV-type ESBLs, on the other hand, are
typically associated to IS26 and disseminate through IS26
dependent mobilization events from the K. pneumoniae
chromosome [5,6]. Eventually, the extended-spectrum
derivates of TEM and SHV enzymes are now ubiquitous.
We detected an ESBL producing E. aerogenes clinical
isolate from Nigeria. Since, the data in the literature
regarding the occurrence and the dissemination of
ESBLs in Nigeria is limited [7,8], we characterized the
beta-lactamases of this isolate by microbiological and
molecular means
Methods
The strain and the susceptibility tests
As t r a i no fEnterobacter aerogenes was isolated and
identified by standard methods from the blood of a two-
year-old male patient, admitted (8th November 1999) to
a tertiary care hospital in a Southwestern city of Nigeria,
with clinical diagnosis of febrile convulsion. The case
note is, however, not available for the history and out-
come of the patient. The strain was identified by API
20E (bioMérieux Marcy l’Etoile, France) according to
the instructions provided by the manufacturer.
Disk diffusion test was performed on Mueller-Hinton
agar (disks and agar media were from Oxoid, Basing-
stoke UK) for the phenotypic identification of ESBLs as
described elsewhere [9]. Briefly, the cefotaxime (CTX;
30-μg )d i s kw a sp l a c e d2 0m ma w a yf r o mt h ea m o x i c i l -
lin (20-μg)-clavulanate (10-μg) (AMC) disk, the ceftazi-
dime (CAZ; 30-μg )d i s kw a sp l a c e da t3 0m md i s t a n c e ,
and the cefepime (FEP; 30-μg) disk was placed at 30
mm distance. For the phenotypic detection of the
AmpC enzyme, a cefoxitin (FOX; 30-μg) disk was placed
on the agar, as well.
The MICs of key antibiotics were determined by the
broth micro-dilution test using Mueller-Hinton Broth
(Oxoid, Basingstoke UK) as recommended by CLSI.
End-points were interpreted after 18 h of incubation at
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included as control strains. Powder forms of antibiotics
were obtained from local companies: ampicillin (Mustafa
Nevzat), piperacillin & tazobactam (Wyeth), clavulanate
(DEPA), cefepime (Bristol-Myers Squibb), cefotaxime
(Toprak), ceftazidime (Glaxo-SmithKline), imipenem
(Merck), meropenem (Astra-Zeneca), ciprofloxacin
(Bayer), gentamicin (Bilim) and tobramycin (Nobel). The
final concentration of clavulanate was 4 mg L
-1.
Plasmid studies
Plasmids were isolated by the alkaline lysis or the Kado
Liu methods [10], run on 0.8% agarose gels and visua-
lized under UV light. Transconjugation and transforma-
tion experiments were performed with E. coli J53-2
(Rif
R) and electro-competent E. coli DH10B strains as
recipients, respectively [11,12].
DNA & RNA isolation, PCR and RT-PCR
DNA templates for PCR experiments were prepared by
simply boiling a dense bacterial suspension in ddH2O
and a 10 min of centrifugation at 16.000 × g. DNA-free
RNAs were isolated with RNeasy Mini Kit (Qiagen), and
run on denaturating gel conditions to check the integ-
rity of RNAs and the lack of visible DNA contamina-
tion. cDNAs were immediately synthesized by random
hexamer primers with Revert Aid first strand cDNA
synthesis kit (Fermentas, Lithuania).
PCR reactions were set in 50 μl final volumes made
up of 1× buffer, 1.5 U Taq polymerase (Fermentas,
Lithuania), 1.5 mM MgCl2, 0.8 mM dNTPs, 50 pmol
primers each. RT-PCR was set up with the same master
mixture except, 1× SYBR Green I (Sigma) was added.
Reactions were prepared on ice and run on Quantica
(Techne) RT-PCR Thermal cycler as described else-
where [13]. Specificity of the product was assessed by
the dissociation curve analysis made by the Quantica
software and the relative mobility of the PCR products
on the agarose gels.
Primers, ShvF1-5’-ATTACCATgAgCgATAACAg-3’
and ShvR1-5’-CATTCAgTTCCgTTTCCC-3’ were used
(55°C annealing temperature) in RealTime-PCR to
amplify a 133 bp fragment internal to blaSHV-12 gene.
The primer ShvF1 and the primer DeoRR1-5’-
CCAggTggTCACCAATgATT-3’ were used (50°C
annealing temperature) to amplify a 927 bp fragment
which extends from the 3’ end of the blaSHV-12 gene to
the 402 bp of the transcriptional regulator gene. To
amplify the entire sequence (861 bp) of blaTEM gene,
the primers TemA-5’-ATgAgTATTCAACAT
TTCCgTg-3’ and TEMD-5’-TTACCAATgCTTAAT-
CAgTgAg-3’ (annealing temp. 52°C) were used.
IEF
Crude cell extracts were prepared by sonication. Analy-
tical isoelectric focusing (IEF) was performed on a 5%
polyacrylamide gel containing ampholytes (pH range, 3-
10; Bio-Rad Laboratories, USA) with a Model 111 Mini
IEF Cell (Bio-Rad). SHV-1 (pI 7.6), OXA-14 (pI 6.2) and
TEM-1 (pI 5.4) were included as references. Enzymes
were focused at a constant 1 W for 45 min and detected
by overlaying the gel with 1 mM nitrocefin solution.
Cloning and sequencing
High molecular weight (HMW) genomic DNA was iso-
lated using the procedure described by Chen and Kuo
[14]. For plasmid DNA isolation, alkaline lysis method
was used (Sambrook and Russell, 2001). Twenty micro-
grams each of HMW genomic DNA and plasmid DNA
were digested with 0.1 units of Bsp143I (Fermentas) for
20 min at 37°C and 0.5 microgram of the cloning vector,
pZero (Invitrogen), was digested with 5 units of BamHI
(Fermentas) for one hour at 37°C. Digested DNA and
the vector were phenol/chloroform extracted and com-
patible arms were ligated overnight at 16°C. Two micro-
liters of ligation mix was then transformed to
electrocompetent E. coli DH10B and the recombinant
clones were selected on agar plates supplemented with
ampicillin (100 mcg/mL) plus zeocin (50 mcg/mL).
Dye terminator cycle sequencing with the ABI Prism
BigDye Terminator kit (Applied Biosystems, Foster City,
Calif.) were used to obtain the sequences. The assay was
carried out according to the standardprotocol. Data was
collected on an ABI 377 automated fluorescence
sequencer.
Results
The isolate, identified as E. aerogenes (EaN146), exhib-
ited a phenotype by the disk diffusion test that is typical
for an AmpC-ESBL co-producer [9]. Briefly, there was
no zone around the FOX disk which was specifically
caused by the over-expressed AmpC enzyme whereas
the zone around the FEB disk was enlarged on the
AMC side, indicating the existence of a Class A ESBL.
By transformation we were able to transfer a narrow
spectrum enzyme encoded on a <7 kb cryptic plasmid
(data not shown) to DH10B recipient (TN146) which
was identified as TEM-1 by sequencing on both sides of
the PCR product.
By shotgun cloning, on the other hand, we recovered a
positive clone (CN146) possessing an ESBL. Sequencing
of the recombinant plasmid (pCEaN146) from this clone
revealed a 5656-bp insert (Figure 1; GenBank accession
# EU534207) on which we determined an open reading
frame (ORF) encoding the ESBL, SHV-12 and an inser-
tion sequence, IS26, upstream (73-bp) of the bla gene
with perfect 14 bp terminal inverted repeats [15]. With
the aid of ORF finding software (MB DNA Analysis
v6.84) and Blast comparison against the sequences sub-
mitted to GenBank we identif i e dt h r e em o r ei n t a c t
ORFs and one another ORF disrupted by IS26. Interest-
ingly, we detected a 9-bp direct repeat sequence
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Page 2 of 5(GTGCTGCTG) flanking on the left and right bound-
aries of a 3002-bp which might be an incomplete trans-
posable unit.
MICs of the strains are shown in Table 1. E. aerogenes
is highly resistant to beta-lactam antibiotics except car-
bapenems. In this strain clavulanate apparently poten-
tiated the activity of cefepime which is relatively stable
against the AmpC type enzyme and hydrolyzed only by
the ESBL, but not enhanced the activity of ceftazidime
which is hydrolyzed by the clavulanate resistant AmpC
enzyme [9].
The IEF experiment is presented in Figure 2. Only two
enzymes (pI 5.4 & pI 9) were visible in the lane of E.
aerogenes, one representing the AmpC (pI 9) and the
other representing the TEM-1 (pI 5.4). At pI 8.2, after
several minutes of incubation a faint band, possibly cor-
responding to SHV12, appeared while the other bands
diffused preventing us to record a good image (data not
shown). To confirm the expression of SHV-12 in
EaN146, we performed a RT-PCR experiment with pri-
mers ShvF1 and ShvR1. Template DNAs were tran-
scribed from the mRNAs of EaN146, CN146 and
TN146. This experiment demonstrated that, although
low in amount, EaN146 is expressing SHV-12.
Discussion
This study characterized the beta-lactamases from a
clinical isolate of E. aerogenes and demonstrated the
occurrence of IS26 associated blaSHV-12 in Nigeria.
SHV-12 was first identified in 1997 in Switzerland and
later reported from various continents including Africa
[16-20]. Reports of SHV-12 producing E. cloacae and
Klebsiella blood isolates from Tanzania and Cameroon
and now E. aerogenes from Nigeria indicate a high ende-
micity of SHV-12 possessing Enterobacteriaceae in the
Western coast of Africa and therefore attract interest.
SHV-1 is supposed to be a species specific enzyme
encoded mainly on the chromosome of K. pneumoniae
[5,21]. Evolutionary analysis of submitted sequences
indicated that extended-spectrum variants evolved on
two branches from blaSHV-1,b o t hm e d i a t e db yI S 26
depended mobilization events from the chromosome of
K. pneumoniae [6]. These analyses revealed that blaSHV-
12evolved from the branch of blaSHV-2a.I n d e e d ,t h e
genes surrounding blaSHV-12 in this study is identical to
the genes surrounding blaSHV-2a in several previously
submitted sequences (GenBank accession #s: X84314
and X53817). This suggests that blaSHV-12 identified in
5656 bp
Tn pA deoR InsA
IRR IRL
DRL DRR
IS
Resolvase
ggcactgttgcaaa tttgcaacagtgcc
SHV-12
26
Figure 1 The schematic map of the cloned insert (5656 bp). ORFs are indicated by empty arrows and repeat regions by dark shaded boxes.
Table 1 The MICs of key antibiotics for SHV-12 producing
E. aerogenes (EaN146), the transformant (TFN146) and
the SHV-12 producing clone (CN146)
Ab
a μg/ml
EaN146 TFN146 CN146
Ampicillin ≥256 ≥256 ≥256
Ampicillin/Clav ≥256 64 32
Cefepime 16 0,5 128
Cefepime/Clav 0,025 0,025 0,025
Ceftazidime 128 0,5 ≥256
Ceftazidime/Clav 64 0,5 4
Cefotaxime 16 <1 >256
Piperacillin 32 >128 >128
Piperacillin/Tazo <4 <4 >128
Imipenem <1 <1 <1
Meropenem <0.25 <0.25 <0.25
Ciprofloxacin <0.25 <0.25 <0.25
Gentamicin >16 <1 <1
Tobramycin 8 <1 <1
aClav, clavulanate (4 μg/ml), Tazo, tazobactam (8 μg/ml)
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evolutionary approach [6].
IS26 is an 820-bp long insertion sequence that typi-
cally generates 8 bp target duplication upon transposi-
tion [15]. It is demonstrated for IS1 that the length of
target site duplication sequences may vary according to
the sequence of the integrated site [22]. This phenom-
enon has not been studied for IS26.I nt h i ss t u d yw e
identified a 9 bp direct repeat on the boundaries of a
3002 bp region bearing blaSHV-12 and the DeoR type
regulator gene. This 3002 bp region may be a replicating
unit.
Data for ESBLs from Nigeria are rare in the literature
[7,8,23]. In a study by Soge et al., CTX-M-15 producing
K. pneumoniae clinical isolates were characterized [7].
In another study, the authors characterized ESBLs by
phenotypic means among E. aerogenes [8].
Conclusions
This is the first study reporting the occurrence and the
genetic support of ESBL blaSHV-12 gene in Nigeria.
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